Luminex® multianalyte liquid suspension array profiling (Xmap®) technology can be used to develop fluorescent covalent microsphere immunoassays (FCMIAs) for numerous types of analytes using indirect, competitive, capture/sandwich as well as other assay formats. We have described FCMIAs for serologic markers to 5 CDC select agents (Bacillus anthracis,Yersinia pestis, Francisella tularensis, ricin toxin, and staphylococcal enterotoxin B; Analytical and Bioanalytical Chemistry 382:1027-34, 2005), IgG antibodies to anthrax toxins (Clin Diag Lab Immunol 11:50-55, 2004), IgG antibodies to 23 pneumococcal polysacchrides (Clin Diag Lab Immunol, 10:744-750, 2003), 3 pesticides/metabolites (Analytical and Bioanalytical Chemistry, 379:368-374, 2004), genetically-modifiedorganism pesticidal proteins (Cry1Ab and Cry3B) and 25 cytokines (IL-1â, IL-1ra, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-13, IL-15, IL-17, TNF-á, IFN- á, IFN-ã, GM-CSF, MIP-1- á, MIP-1-â, IP-10, MIG, Eotaxin, RANTES, and MCP-1). In general, FCMIAs are faster, more sensitive, use less sample, are more precise, and have higher throughput than any competing assay technology. In this presentation, we describe the performance of these analyses and their usefulness as diagnostic and environmental methods, comparing them to traditional enzyme-linked, immunosorbant assays (ELISAs) and classical instrumental methods, such as gas- and high performance liquid chromatography.
BHAB, Centers for Disease Control and Prevention/NIOSH, 4676 Columbia Parkway, Cincinnati, OH 45226